Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Fig. 2 | BMC Medicine

Fig. 2

From: Promising new drugs and therapeutic approaches for treatment of ovarian cancer—targeting the hallmarks of cancer

Fig. 2

Inducing or accessing vasculature. In cancer, angiogenesis is stimulated by proangiogenic factors such as vascular endothelial growth factor (VEGF), tumor growth factor β (TGF β), and fibroblast growth factor (FGF), interacting with their receptors VEGFR, TGFR, and FGFR. Binding of angiopoietin to Tie2 receptor inhibits vascular maturation and platelet-derived growth factor (PDGF) promotes proliferation of pericytes. Increased activity of depictured signaling pathways leads to leaky neovasculature with high levels of apoptosis and excessive vessel branching. Currently ongoing and recently completed phase III trials targeting those pathways are listed in the table. This figure was created using Biorender.com [63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85]

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us